CORONANSECORONA Remedies LimitedLowNeutral
Announced Tue, 26 May · 12:44 IST

CORONA Remedies Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Ownership Changes View source PDF

CORONA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-0.7%1-day move
₹1690.00
prior close
₹1700.20
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.1-0.1-0.2-0.3-0.7-0.7-0.2+0.1+1.0+1.9+5.5+16.3+24.3
Up moveDown movePending
AI summary

Three key promoters of CORONA Remedies Limited (Dr. Kirtikumar Mehta - Chairman, Nirav Mehta - Managing Director & CEO, and Ankur Mehta - Joint Managing Director) have submitted declarations under Regulation 31(4) of SEBI SAST Regulations, 2011. Each declaration confirms that neither they nor their Persons Acting in Concert (PAC) have created any encumbrance (pledge) on the company's equity shares during FY 2025-2026. The declarations list 23 entities including family members and two LLPs (NKM Nextgen LLP and KLNext Enterprise LLP) as part of the promoter group.

Likely market impact

This is a positive compliance disclosure indicating that promoter shareholding remains unencumbered, meaning lenders have not claimed shares as collateral. This suggests financial stability in the promoter group and removes any near-term dilution risk from forced pledge invocation.